In Zusammenarbeit mit PD Dr. Tobias Ruck und Dr. Christopher Nelke
On December 16th, the EMA voted against marketing authorisation for Aduhelm (aducanumab), which is intended for the treatment of early Alzheimer’s disease (AD). The EMA’s decision was preceded by accelerated approval for Aduhelm by the FDA. We acknowledge the rigorous scientific assessment performed by the EMA, but are concerned that depriving European patients of a potential treatment for AD is likely to have a negative impact. In this letter, we argue for the approval of Aduhelm for early AD under the premise of a conditional market authorization in a controlled framework.
„Open LETTERin response to the European Medicines Agency’s refusal of marketing authorisation for Aduhelm (aducanumab)“ weiterlesen